Daniel Paulson, MD

Title: Vice President of Clinical Development

Organization: Capricor Therapeutics

Bio: Dr. Daniel Paulson joined Capricor in 2022 serving as Vice President of Clinical Development where he will oversee Capricor’s therapeutic pipeline consisting of CAP-1002 as well as the development efforts with Capricor’s expanding exosome platform. He has over 20 years of diverse drug development experience in trial operations and global drug development. Prior to Capricor, he was with Bayer Healthcare, where he held the position of Vice President, Development where he was the Group Head for Established Products and Corporate Social Responsibility. During his tenure with Bayer, he oversaw a diverse range of therapeutic areas including cardiovascular risk management and metabolism as well as anti-infectives. His team designed and executed numerous development programs leading to successful drug approvals in many regions of the world including the US, EU and Asia. Several of these programs were targeting orphan/rare disease indications. One program, focused on Chagas Disease, obtained a priority review voucher, first and only one obtained by Bayer HealthCare to date. Additionally, Dr. Paulson was involved with indication evaluation and expansion efforts for early development assets. During his 13 years with Bayer, he worked in Beijing, China for 5 years assisting in the initiation of the global clinical development function and growth of Bayer’s first Global Development site in Asia. Prior to joining Bayer, Dr. Paulson acted as the Director for Cardiothrombosis at Sanofi’s US Clinical Research Unit. He directed teams that executed all Sanofi’s US cardiovascular trials. The group expanded tremendously under Dr. Paulson’s leadership and was instrumental in the completion of many key phase II and III programs for Sanofi leading to several drug approvals in the US. Dr. Paulson has a B.S. in biology from the University of Minnesota. He received his M.D. degree from the Medical College of Virginia (MCV) in Richmond, Virginia. After his completion of his Internal Medicine internship and residency, he served as a Medical Chief Resident for the Internal Medicine program. He subsequently joined the faculty at Medical College of Virginia where he practiced full-time in the Veterans Affairs Medical Center for eight years acting as the Director for one of the Primary Care Group practices and established a successful Clinical research operation within the Primary Care Department.

Beyond Dystrophin Panel

This conference session provides insight and updates from companies whose therapies target critical aspects of the Duchenne disease process that occur alongside reductions in dystrophin.

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

Mindy Cameron

Patient Advocacy Lead

Santhera Pharmaceuticals

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

Daniel Paulson, MD

Vice President of Clinical Development

Capricor Therapeutics

Han Phan, MD


Rare Disease Research, LLC